GAITHERSBURG, Md., June 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, is pleased to announce that it has been recognized as one of The Washington Post Top Workplaces.
The Washington Post Top Workplaces are determined based solely on employee feedback. The employee survey was conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement. Over the past year, more than 5,000 organizations in the U.S. have turned to WorkplaceDynamics to better understand what's on the minds of their employees. Through its workplace improvement offerings, WorkplaceDynamics provides solutions, training and tools to help clients improve their workplace.
"Novavax' success can be measured by the contribution of its most important asset: its talented, capable and committed employees. We make it a priority to provide a work environment that supports the individual, while at the same time celebrating the teamwork necessary to achieve great things," stated Stanley C. Erck, President and CEO. "It's been my great privilege to work with each and every one of them."
Jill Hoyt, Novavax' Executive Director of Human Resources, added. "Receiving this recognition as a top workplace in the Washington D.C. area is a true honor. This recognition reinforces all the hard work Novavax' employees have made to establish the company as a leader in recombinant vaccine technology, and as a thriving, collegial place to work, built around a culture of collective success."
The Washington Post published the complete list of Top Workplaces on June 22nd. For more information about the Top Workplaces lists and WorkplaceDynamics, please visit www.topworkplaces.com and www.workplacedynamics.com.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer